FDA approves expanded indication for Lilly’s Jaypirca
The regulatory decision is supported by data from the primary analysis of the Phase III BRUIN CLL-313 clinical study.
Drug Development
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Bristol Myers Squibb secures expanded US approval for Camzyos
BioMarin and Profluent partner on AI-designed enzyme therapies
OBIO marks $704m funding milestone for Canadian health tech ventures
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
AstraZeneca to invest $2bn in Summit for ADC combination therapies
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
